Eli Lilly, Novo Nordisk lead revenue boom in the 'always tricky' Q4

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. Of the world’s 22 biopharma companies that had reported quarterly revenue of at least $2 billion by Feb. 24, only one posted a year-over-year decline.